Vnitr Lek 2009, 55(1):45-53

Effectiveness of TNF antagonists in routine clinical practice and costs

M. Prokeš
INFOPHARM a.s., Praha, ředitel PharmDr. Josef Suchopár

A comparison of effectiveness of TNF antagonists adalimumab, infliximab and etanercept in the treatment of rheumatoid arthritis (RA) was made, which was derived from studies provided abroad based on routine clinical practice. The calculation of cost-effectiveness of each TNF antagonist for Czech Republic was made on the basis of Dutch DREAM registry of patients with RA (Kiewit et al, 2008). The prices of therapy of all three TNF antagonists are similar in the first year of treatment of patients with average weight, in the second year the price of infliximab is lower, but only in the case of patients where the doses do not reach 4 amp. of infliximab. Clinical effectiveness was evaluated in DAS28 and HAQ units. Cost-effectiveness of all TNF antagonists was similar, when 2 amp. of infliximab per dose phycician considered sufficient, but when patients were given higher doses of infliximab the trend to lower cost-effectiveness of infliximab compared to adalimumab and etanercept was observed.

Keywords: TNF antagonists; rheumatoid arthritis; cost-effectiveness

Received: July 28, 2008; Accepted: October 15, 2008; Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M. Effectiveness of TNF antagonists in routine clinical practice and costs. Vnitr Lek. 2009;55(1):45-53.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pavelka K, Rovenský J et al. Farmakoterapie revmatických onemocnění. Praha: Grada Publishing 2005: 181-215.
    2. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 2003; I: 20. http://www.hqlo.com/content/1/1/20. Go to original source... Go to PubMed...
    3. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid artritis. N Eng J Med 2000; 343: 1594-1600. Go to original source... Go to PubMed...
    4. Moreland LW, Weinblatt ME, Keystone EC et al. Etanercept Treatment in Adults with Established Rheumatoid Artritis: 7 Years of Clinical Experience. J Rheumatol 2006; 33: 854-861. Go to PubMed...
    5. Weinblatt ME, Keystone EC, Furst DE et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753-759. Go to original source... Go to PubMed...
    6. Hyrich KM, Lung M, Watson KD et al. Outcomes After Switching From One Anti-Tumor Nectrosis Factor α Agent in Patients With Rheumatoid Arthritis. Arthritis Rheum 2007; 56: 13-20. Go to original source... Go to PubMed...
    7. Zink A, Strangfeld A, Schneider M et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis in an Observational Cohort Study. Arthritis Rheumatism 2006; 54: 3399-3407. Go to original source... Go to PubMed...
    8. Duclos M, Gossec L, Ruyssen-Witrand A et al. Retention Rates of Tumor Necrosis Factor Blockers in Daily Practice in 770 Rheumatic Patients. J Rheumatol 2006; 33: 2433-2439. Go to PubMed...
    9. Finckh A, Simard JF, Gabay C et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-752. Go to original source... Go to PubMed...
    10. Kievit W, Adang EM, Fransen HH et al. The effectiveness and medication costs of three anti-TNF-α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. ARD Online First, published on January 3, 2008, as 10.1136/ard.2007.083675.
    11. Kolektiv autorů. Základy farmakoekonomiky pro lékaře, lékárníky a další pracovníky ve zdravotnictví. ČFES 2007.
    12. Wailoo AJ, Bansback N, Brennan A et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arhtritis Rheum 2008; 58: 939-946. Go to original source... Go to PubMed...
    13. Brennan A, Bansback N, Noxon R et al. Modelling the cost effectiveness of THF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007; 46: 1345-1354. Go to original source... Go to PubMed...
    14. Breedveld FC, Weisman MH, Kavanaugh AF et al. A multucenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheumatism 2006; 54: 26-37. Go to original source... Go to PubMed...
    15. Emery B, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-382. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.